Suven Life Sciences Reaches 76% Masupirdine Phase 3 Enrollment

Suven Life Sciences announced 76% enrollment completion in its 375-patient global Phase 3 trial for Masupirdine treating Alzheimer's agitation.
The company targets Last Patient In by September 2026 and data readout by April 2027 for this CNS disorder treatment.
Masupirdine is a selective 5-HT6 receptor antagonist positioned as a non-dopaminergic, non-sedative approach to Alzheimer's agitation management.